China Life’s H2 NBV Growth Was Weaker Than Expected; Dividend Payment Missed

""
Securities In This Article
China Life Insurance Co Ltd Class A
(601628)

We lower our fair value estimate for China Life 601628 to HKD 20 per H-share after its 2022 results, reflecting lower projections for new business value growth and investment returns in 2023. The results were weaker than expected, with full-year 2022 total revenue and net profit growth declining 3.8% and 37% respectively from 2021. The profit decline was mainly driven by sharply lower realized investment gains. NBV declined 20% from 2021. The contraction was smaller than peers including Ping An and CPIC, but still misses our expectation for negative 20% growth. Decelerating NBV growth in the fourth quarter was due to heightened coronavirus restrictions and shifting focus to preparations for its 2023 New Year sales campaign. The fourth quarter also saw a wider quarter-on-quarter contraction in agent headcount to 7% from about 5% in the first three quarters of 2022.

China Life’s H-shares reacted negatively to its wider-than-peer net profit contraction on March 30. We suspect investors are disappointed over the 25% reduction in the 2022 dividend payment. By contrast, Ping An and CPIC increased dividends per share by about 2% despite net profits declining 18% and 8% respectively from 2021. The market has long been concerned about China Life’s higher-than-peer earnings volatility as a pure life insurer. We would prefer China Life to base its dividend payout on operating profit, which is what its major peers do, rather than more volatile net profit.

H-shares remain significantly undervalued, trading near the historical trough valuation of 0.2 times 2023 price/embedded value. We think the risks are more than priced in. We think agent headcount has bottomed as it has shrunk by nearly 60% from its peak in 2019. Our estimated NBV per agent increased 19% year on year in 2022. Management hinted the firm saw a strong pickup in March sales against the first two months of 2023. We expect 2023 NBV to grow at a mid-single-digit pace in 2023, but the first quarter should remain sluggish.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Iris Tan, CFA

Senior Equity Analyst
More from Author

Iris Tan, CFA is a senior equity analyst, Asia, for Morningstar*. She currently covers banking and insurance in China. Main companies in her coverage include China’s big four banks, China Merchants Bank, China Life Insurance, Ping An Insurance, PICC Group and AIA Group. Before covering China banks and insurers, she ever covered China real estate firms, securities firms and consumer companies.

Before joining Morningstar in 2006, she was a financial analyst for San Miguel Brewery, responsible for compiling economic analysis, industry & investment research on China’s brewery markets. Prior to this role, she was a research assistant for GTA Information Technology, participating in the development of Securities Analysis System cooperated with Venture Capital Investment Research Institute of Hong Kong Polytechnic University, mainly in the functional design of industry analysis and financial analysis of listed companies.

Tan holds a Master of Science degree in finance from the Strathclyde Business School, a triple-accredited business school (AACSB, EQUIS and AMBA) in University of Strathclyde. She also holds the Chartered Financial Analyst® designation.

* Morningstar (Shenzhen) Ltd. (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center